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We present the first clinical evidence of advanced squamous non-small cell lung cancer 
with severe thrombocytopenia showing dramatic improvement after first-line treatment 
with pembrolizumab plus autologous cytokine-induced killer cells.
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INtRoDUCtIoN
Despite great progress in the management of advanced non-small cell lung cancer (NSCLC), 
chemotherapy remains the therapeutic mainstay for squamous NSCLC. However, only patients 
with good performance status and sufficient organ function are likely to benefit from this approach. 
Immunotherapy is an evolving treatment approach based on the use of the immune system to treat 
cancer. Programed death 1 (PD-1), functioning as an immune checkpoint, plays an important 
role in tumor immune escape by preventing the activation of T-cells. Nivolumab, a PD-1 blocking 
antibody, was recently approved by the US Food and Drug Administration (FDA) for patients with 
advanced NSCLC whose disease progressed during or after platinum-based chemotherapy (1, 2). 
Similarly, FDA has granted approval for Keytruda (pembrolizumab) to treat patients with advanced 
(metastatic) NSCLC whose disease has progressed after other treatments and with tumors that 
express a protein called PD-L1 (3). However, unfortunately, only a subset of patients will benefit 
from PD-1 blocking antibody. Although some clinical trials suggest that cytokine-induced killer cell 
(CIK cell) immunotherapy could improve the clinical outcome of advanced squamous cell NSCLC, 
the treatment is mainly combined with chemotherapy. A recent study indicated that PD-1 blocking 
antibody may improve the efficacy of adoptive cell therapy in human cancer (4, 5). We report here 
the successful management of a case of advanced squamous NSCLC with severe thrombocytopenia, 
treated with pembrolizumab combined with autologous CIK cells as first-line therapy.
FIGURe 1 | Ct scans of the patient before and after pembrolizumab and CIK combination treatment for advanced NsCLC. Tumor masses can be seen 
in the left lung hilum and mediastinal lymph nodes of the patient before initiation of immunotherapy. The masses significantly reduced in size on CT obtained 30 and 
60 days after treatment, indicating good response to combination therapy.
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Case pReseNtatIoN
A 73-year-old man presented at our institution with complaints 
of fever, cough, and hemoptysis, a computed tomography (CT) 
and positron emission computed tomography (PET-CT) scan 
revealed a left hilar mass with multiple pathologically enlarged 
mediastinal lymph nodes and left adrenal masses (Figures  1 
and 2). Bronchoscopy demonstrated an endobronchial tumor 
obstructing the left bronchus; biopsy revealed poorly differenti-
ated squamous cell carcinoma. Serum tumor markers SCC and 
Cyfra21-1 were 7.7 and 10.2 μg/L, respectively. Complete blood 
count analysis showed that the patient had thrombocytopenia 
(platelet count 5–17  ×  109/L). A bone marrow aspirate and 
PET-CT revealed no abnormalities of bone or bone marrow. 
The patient was not appropriate for chemo-radiotherapy and 
at a high risk of massive hemorrhage due to the endobronchial 
disease coupled with severe thrombocytopenia. Under patient’s 
informed consent, pembrolizumab combined with autologous 
CIK cell therapy was initiated as first-line treatment. Meanwhile, 
written permission from the patient for publication of clinical 
data was obtained.
Cytokine-induced killer cells are a group of immune effec-
tor cells featuring a mixed T- and natural killer (NK) cell-like 
phenotype, which are generated by incubation of mononuclear 
cells from peripheral blood with an anti-CD3 monoclonal anti-
body, interleukin (IL)-2, IL-1, and interferon (IFN)-γ (6, 7). The 
protocol of CIK preparation was approved by the Institutional 
Ethics Committee. Peripheral blood mononuclear cells (PBMCs) 
FIGURe 2 | pet-Ct scans before and after treatment. PET-CT May 2015 before treatment showing high glucose metabolism in left hilar mass, multiple 
mediastinal lymph nodes, and left adrenal masses. PET-CT September 2015 after five courses of pembrolizumab and three courses of CIK cell therapy showing 
significantly reduction in tumor mass and FDG uptake.
December 2015 | Volume 6 | Article 6333
Hui et al. Lung Cancer Treated with Immunotherapy
Frontiers in Immunology | www.frontiersin.org
December 2015 | Volume 6 | Article 6334
Hui et al. Lung Cancer Treated with Immunotherapy
Frontiers in Immunology | www.frontiersin.org
were collected from patient using a Cobe Spectra Apheresis 
System (CaridianBCT, Lakewood, CO, USA), and cultured in 
X-VIVO 20 serum-free medium (Cambrex, East Rutherford, NJ, 
USA) containing 50 ng/mL anti-CD3 antibody to stimulate CIK 
cell growth, 100 U/mL recombinant human IL-1a (e-Bioscience, 
San Diego, CA, USA), and 1,000  U/mL recombinant human 
IFN-γ (Peprotech, Rocky Hill, NJ, USA), at 37°C with 5% CO2 
for 24 h. Then, 300 U/mL recombinant human IL-2 (Peprotech) 
was added to the media. IL-2- and IFN-γ-containing medium 
was added to the culture system every 5 days. On day 14, CIK 
cells were harvested and analyzed for phenotype and cytotoxicity. 
Safety testing was performed during the course of cell culture. All 
products were free of bacterial and fungal contamination, nega-
tive for mycoplasma, and contained <5 Eu endotoxin. Patient was 
treated with intravenous infusions of (13.07 ± 1.37) × 109 CIK 
cells at days 15 and 16 of each cycle. These cells have higher prolif-
eration rate, cytolytic activities, and non-MHC-restricted killing 
of tumor cells (8). After two courses of the immune checkpoint 
inhibitor (pembrolizumab 2  mg/kg every 3  weeks) and one 
course of CIK cell therapy (every month), a CT scan revealed a 
FIGURe 3 | programed death 1 and granzyme B expression on peripheral lymphocytes. (a–C) show PD-1 and granzyme B expression on peripheral CD4+ 
and CD8+ T cells before therapy (May 2015); (a–c) show PD-1 and granzyme B expression on CD4+ and CD8+ T cells after achieving PR (September 2015).
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rapid regression in the tumor size (Figure 1). Serum tumor mark-
ers also showed a significant decrease: SCC 1.6 μg/L, Cyfra21-1 
1.62 μg/L. Another course of pembrolizumab and CIK cell immu-
notherapy was given and a subsequent CT scan showed further 
reduction (achieved partial response according to RECIST1.1 
criteria) (Figure  1). After five courses of pembrolizumab and 
three courses of CIK cell therapy, a PET-CT scan showed that 
both tumor burden and radioactivity were significantly decreased 
(Figure 2). PD-1 expression on peripheral CD4+ and CD8+ T 
cells showed dramatically decrease after therapy (32.1 vs.1.4, 46.0 
vs. 0%), and there was mild increase in granzyme B expression on 
CD8+ T cells (66.7 vs. 68.3%) (Figure 3). The patient developed 
low-grade fatigue, decreased appetite and vitiligo, without seri-
ous hemorrhage during treatment, and platelet count rises to 
60–144 × 109/L.
DIsCUssIoN
Our work represents the first clinical evidence that PD-1 block-
ing antibody plus autologous CIK cell therapy is well tolerated 
and highly effective in an advanced squamous NSCLC patient 
with severe thrombocytopenia. Pembrolizumab works by 
blocking the PD-1 and keeping its ligands PD-L1 and PD-L2 
from binding to it to reduce inhibitory signaling and restore 
the patient’s natural tumor specific T-cell-mediated immune 
responses and provide a favorable circumstance for CIK cell 
infusion. CIK cells could exert a more potent antitumor effect 
in a tumor microenvironment where the immunoinhibitory 
effect of PD-L1 is neutralized. The synergistic activity between 
checkpoint inhibitors and CIK cell infusion could represent an 
effective therapeutic strategy with rapid onset, which differs 
from traditional chemotherapy and targeted agents (9). This 
is only a feasibility case report and our assumption that there 
is synergy between the antibody and CIK cell is not justified, 
further research is being carried out in our institution to validate 
these findings.
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